Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Eni will guarantee Dompé researchers access to its laboratories, support from the company's specialized staff, and use of its HPC5 supercomputer
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Increased capability to produce medicines for challenging diseases including cancer
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Lokavant provides clinical trial intelligence
Advances Amgen's mission to serve patients with rare disease medicines
WINLEVI works differently from any other topical acne treatment
Subscribe To Our Newsletter & Stay Updated
